Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Shares Issued (2021 - 2025)

Historic Shares Issued for Maxcyte (MXCT) over the last 5 years, with Q3 2025 value amounting to $14000.0.

  • Maxcyte's Shares Issued fell 9385.96% to $14000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $635000.0, marking a year-over-year decrease of 6038.68%. This contributed to the annual value of $1.6 million for FY2024, which is 1478.12% down from last year.
  • As of Q3 2025, Maxcyte's Shares Issued stood at $14000.0, which was down 9385.96% from $20000.0 recorded in Q2 2025.
  • Maxcyte's 5-year Shares Issued high stood at $51.8 million for Q1 2021, and its period low was -$51.8 million during Q4 2021.
  • For the 5-year period, Maxcyte's Shares Issued averaged around $398588.2, with its median value being $325500.0 (2022).
  • Its Shares Issued has fluctuated over the past 5 years, first tumbled by 9827.71% in 2022, then surged by 51621.62% in 2024.
  • Quarter analysis of 5 years shows Maxcyte's Shares Issued stood at -$51.8 million in 2021, then skyrocketed by 102.37% to $1.2 million in 2022, then tumbled by 81.72% to $224000.0 in 2023, then fell by 2.68% to $218000.0 in 2024, then plummeted by 93.58% to $14000.0 in 2025.
  • Its last three reported values are $14000.0 in Q3 2025, $20000.0 for Q2 2025, and $383000.0 during Q1 2025.